Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Kindos
Chengdu, Sichuan, China
- Ownership
- Private
- Development stage
- Other
01
Overview
Kindos is a leading Chinese sterile injectables and biopharmaceutical CDMO/CRDMO with FDA and NMPA-certified facilities, with multiple products approved for US and international markets, including commercial sales of dacarbazine injection (FDA 2024). It leverages advanced isolator aseptic manufacturing and develops both small molecules and biologics, with an expanding global footprint[1][2][3][4].
- Therapeutic areas
- OncologyInfectious DiseasesImmunologyCardiovascular
- Modalities
- Small moleculeMonoclonal antibodyAntibody-drug conjugateNucleic acid drugmRNA-based drugsVaccine
- Industry
- Biotech
02
Partnerships
Multiple global biopharmaceutical companies (not individually disclosed; “world’s top 500 pharmaceutical companies” as clients[3])
Beyond the preview
Go deeper on Kindos.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kindos.